ADVFN - Advanced Financial Network.
HOME» NYSE » M » MDT Stock Price » MDT Stock News

Medtronic Share News

 Medtronic, Inc. Stock Price
MDT Stock Price
 Medtronic, Inc. Stock Chart
MDT Stock Chart
 Medtronic, Inc. Stock News
MDT Stock News
 Medtronic, Inc. Company Information
MDT Company Information
 Medtronic, Inc. Stock Trades
MDT Stock Trades

St Jude Defibrillator Lead Performed Worse Than Competitor Lead -Study

By Anjali Athavaley Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- St. Jude Medical Inc.'s (STJ) Riata defibrillator leads performed significantly worse than Medtronic Inc.'s (MDT) Quattro leads, according to results from a multicenter study presented at a medical meeting Thursday. St. Jude stopped selling the Riata leads in 2010, but about 79,000 are still implanted in patients in the U.S. St. Jude said last year it was recalling them due to a tendency for the metal wires to wear through their silicone covering. Data in the study, presented at the Heart Rhythm Society meeting in Boston, was collected retrospectively from seven centers. Researchers evaluated the leads for all causes of failure, including cases where cables wore through their coating and electrical malfunctions. Riata, but not Riata ST, leads performed significantly worse than Quattro, according to the study. But follow-up for Riata ST was shorter than it was for Riata. The study also found that nearly a third of leads with exposed cables were malfunctioning. St. Jude said in a statement that the data is consistent with the company's findings that significant design changes implemented in the Riata ST leads resulted in improved performance compared to the Riata leads. In March, a study authored by Robert G. Hauser, a Minnesota cardiologist, tied a malfunction in Riata to at least 20 deaths. Dr. Hauser said the deaths alleged from Riata malfunctions were about nine times greater than Quattro. Last month, St. Jude said it was seeking a retraction of the study, published in the Heart Rhythm Journal. The company says Dr. Hauser undercounted deaths linked to Quattro. St. Jude shares were up 2.3% to $40.12 in recent trading. The stock is down 24% in the last year. -By Anjali Athavaley, Dow Jones Newswires; 212-416-4912;

Stock News for Medtronic (MDT)
09/28/201621:00:00FDA Approves Medtronic's New Automated Insulin Pump -- Update
09/28/201618:46:00FDA Approves Medtronic's New Automated Insulin Pump
09/28/201616:50:00FDA Approves Medtronic's New Automated Insulin Pump
09/28/201616:42:00FDA Approves Medtronic's New Automated Insulin Pump
09/28/201616:27:03Statement of Changes in Beneficial Ownership (4)
09/28/201613:19:35Medtronic Receives FDA Approval for World's First Hybrid Closed...
09/28/201609:00:20Medtronic Receives FDA Clearance of TrailBlazer Angled Peripheral...
09/27/201609:00:35Medtronic Announces First Live Experience of Sugar.IQ with Watson...
09/26/201608:01:27Medtronic's StealthStation® Cranial Software Receives FDA Clearance...
09/20/201612:30:12Medtronic Valiant Captivia Demonstrates Safety and Efficacy at...
09/19/201617:07:45Statement of Changes in Beneficial Ownership (4)
09/19/201616:46:54Statement of Changes in Beneficial Ownership (4)
09/19/201612:45:20New Data Presented in VIVA Late Breaking Clinical Trials Demonstrate...
09/19/201609:30:19Analysis Shows Positive Association Between Cardiac Resynchronization...
09/19/201607:00:00AxoGen, Inc. Appoints Amy Wendell to Board of Directors  
09/15/201608:30:29The Journal of the American Medical Association Publishes Medtronic's...
09/15/201608:00:46Medtronic Names Mark Ploof Senior Vice President of Global Operations...
09/14/201609:00:25Medtronic Announces Approval and Launch of Reveal LINQ(TM) Insertable...
09/13/201611:00:43Medtronic Receives FDA Approval of First Drug-Coated Balloon...
09/12/201609:00:12New ESC Guidelines Support Recent Medtronic Innovations for...

Medtronic and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations